Therapeutic area intelligence for Botulinum Toxin with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Merz Pharmaceuticals →

Assets

Ipsen →

MHRA →

Updated →

Recent signals(4)

RegulatoryJuly 16, 2026

MHRA Strengthens Warnings for Botulinum Toxin Type A Products Due to Botulism Cases

The MHRA has issued updated safety warnings for botulinum toxin type A products due to rare cases of botulism.

RegulatoryJuly 16, 2026

Updated Warnings on Botulinum Toxin Type A Products Due to Iatrogenic Botulism Risk

Iatrogenic botulism cases have been reported following the use of botulinum toxin type A products, indicating a risk of toxin effects extending beyond treatment areas.

RegulatoryJuly 1, 2026

FDA Accepts Supplement for Xeomin (incobotulinumtoxinA) by Merz Pharmaceuticals

The FDA has accepted a supplemental application for Xeomin, a botulinum toxin product from Merz Pharmaceuticals.

ClinicalJune 30, 2026

Study on Botulinum Toxin-A for Temporomandibular Myofascial Pain Outcomes

This study aims to evaluate the effectiveness of botulinum toxin-A compared to normal saline in treating temporomandibular myofascial pain.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.